164 related articles for article (PubMed ID: 10353255)
1. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues.
Fu L; Liu SH; Cheng YC
Biochem Pharmacol; 1999 Jun; 57(12):1351-9. PubMed ID: 10353255
[TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.
Chin R; Shaw T; Torresi J; Sozzi V; Trautwein C; Bock T; Manns M; Isom H; Furman P; Locarnini S
Antimicrob Agents Chemother; 2001 Sep; 45(9):2495-501. PubMed ID: 11502520
[TBL] [Abstract][Full Text] [Related]
3. Characterization of novel human hepatoma cell lines with stable hepatitis B virus secretion for evaluating new compounds against lamivudine- and penciclovir-resistant virus.
Fu L; Cheng YC
Antimicrob Agents Chemother; 2000 Dec; 44(12):3402-7. PubMed ID: 11083647
[TBL] [Abstract][Full Text] [Related]
4. Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine.
Zhu YL; Dutschman DE; Liu SH; Bridges EG; Cheng YC
Antimicrob Agents Chemother; 1998 Jul; 42(7):1805-10. PubMed ID: 9661025
[TBL] [Abstract][Full Text] [Related]
5. Reverse transcriptase activity of hepatitis B virus (HBV) DNA polymerase within core capsid: interaction with deoxynucleoside triphosphates and anti-HBV L-deoxynucleoside analog triphosphates.
Lam W; Li Y; Liou JY; Dutschman GE; Cheng YC
Mol Pharmacol; 2004 Feb; 65(2):400-6. PubMed ID: 14742682
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir.
Ying C; De Clercq E; Nicholson W; Furman P; Neyts J
J Viral Hepat; 2000 Mar; 7(2):161-5. PubMed ID: 10760047
[TBL] [Abstract][Full Text] [Related]
7. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).
Das K; Xiong X; Yang H; Westland CE; Gibbs CS; Sarafianos SG; Arnold E
J Virol; 2001 May; 75(10):4771-9. PubMed ID: 11312349
[TBL] [Abstract][Full Text] [Related]
8. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
10. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance.
Fu L; Cheng YC
Biochem Pharmacol; 1998 May; 55(10):1567-72. PubMed ID: 9633992
[TBL] [Abstract][Full Text] [Related]
11. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir.
Colledge D; Civitico G; Locarnini S; Shaw T
Antimicrob Agents Chemother; 2000 Mar; 44(3):551-60. PubMed ID: 10681317
[TBL] [Abstract][Full Text] [Related]
12. Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.
Walters KA; Tipples GA; Allen MI; Condreay LD; Addison WR; Tyrrell L
Antimicrob Agents Chemother; 2003 Jun; 47(6):1936-42. PubMed ID: 12760870
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.
Ono-Nita SK; Kato N; Shiratori Y; Lan KH; Yoshida H; Carrilho FJ; Omata M
J Clin Invest; 1999 Jun; 103(12):1635-40. PubMed ID: 10377169
[TBL] [Abstract][Full Text] [Related]
15. A novel mutation pattern emerging during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment.
Karatayli E; Karayalçin S; Karaaslan H; Kayhan H; Türkyilmaz AR; Sahin F; Yurdaydin C; Bozdayi AM
Antivir Ther; 2007; 12(5):761-8. PubMed ID: 17713159
[TBL] [Abstract][Full Text] [Related]
16. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.
Delaney WE; Edwards R; Colledge D; Shaw T; Torresi J; Miller TG; Isom HC; Bock CT; Manns MP; Trautwein C; Locarnini S
Antimicrob Agents Chemother; 2001 Jun; 45(6):1705-13. PubMed ID: 11353615
[TBL] [Abstract][Full Text] [Related]
17. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
[TBL] [Abstract][Full Text] [Related]
18. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.
Delaney WE; Locarnini S; Shaw T
Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses.
Seignères B; Pichoud C; Martin P; Furman P; Trépo C; Zoulim F
Hepatology; 2002 Sep; 36(3):710-22. PubMed ID: 12198665
[TBL] [Abstract][Full Text] [Related]
20. Potential use of antiviral L(-)nucleoside analogues for the prevention or treatment of viral associated cancers.
Cheng YC
Cancer Lett; 2001 Jan; 162 Suppl():S33-S37. PubMed ID: 11164188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]